BCM-95® (CURCUGREEN®), 20 Mar 2015
Published on : Eur Neuropsychopharmacol . 2015 Jan;25(1):38-50. doi: 10.1016/j.euroneuro.2014.11.015. Epub 2014 Dec 5.

Curcumin in major depression & Peripheral biomarkers

Adrian L Lopresti 1, Michael Maes 2, Marc J M Meddens 3, Garth L Maker 4, Eddy Arnoldussen 3, Peter D Drummond 5

PMID: 25523883 DOI: 10.1016/j.euroneuro.2014.11.015


Curcumin and major depression: A randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change

Adrian L. Loprestia, Michael Maesb, Marc J.M. Meddensd, Garth L. Makere, Eddy Arnoldussend, Peter D. Drummonda

doi.10.1016|j.2014.11.015

Abstract: A recent randomised, double-blind, placebo controlled study conducted by our research group, provided partial support for the efficacy of supplementation with a patented curcumin extract (500 mg, twice daily) for 8 weeks in reducing depressive symptoms in people with major depressive disorder.

Procedure: Participants were randomly and equally allocated into two groups (placebo and curcumin) using a randomisation calculator. Both curcumin and placebo capsules were packed in identical containers labelled by participant code numbers and allocation was assigned by the first author according to order of participant enrolment in the study. As no previous clinical study has investigated the effect of curcumin on most of the measured biomarkers, data to complete an a priori power analysis could not be determined. However, to achieve a power of 0.8, sample size estimates were based on the assumption of a moderate effect size of 0.4 indicating a total sample size of approximately 50 was required for this study.

Results: Univariate tests exploring the effects of the group by time on the different individual urinary biomarkers revealed significant group time interactions.

Conclusion: Important preliminary findings were identified as Urinary cortisol levels trended downward following placebo treatment and trended upward following curcumin treatment, resulting in significant between-group differences. Determining reasons for these differences are difficult as they were not related to treatment outcome. Speculatively, curcumin may have enhanced endothelin or leptin receptor sensitivity or some other mechanism associated with biomarkers which, in turn, had antidepressant effects.

Limitations: The relatively small samples size and the large number of statistical analyses used in this study limits the reliability and statistical power associated with the findings.


Keywords

  • antidepressant
  • bcm
  • BCM-95
  • bcm95
  • clinical study
  • curcugreen
  • Curcumin
  • research
  • turmeric
  • turmeric extract

References


  1. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients.
    
    Belcaro GCesarone MRDugall MPellegrini LLedda AGrossi MGTogni SAppendino G
    Altern Med Rev, (4):337-344 2010
    MED: 21194249

  2. HPA axis and aging in depression: systematic review and meta-analysis
    
    Belvederi
    
    Psychoneuroendocrinology 2014

  3. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study.
    
    Bergman JMiodownik CBersudsky YSokolik SLerner PPKreinin APolakiewicz JLerner V
    Clin Neuropharmacol, (3):73-77 2013
    MED: 23673908

  4. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.
    
    Biomarkers Definitions Working Group.
    Clin Pharmacol Ther, (3):89-95 2001
    MED: 11240971

  5. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response.
    
    Blier PGobbi GHaddjeri NSantarelli LMathew GHen R
    J Psychiatry Neurosci, (3):208-218 2004
    MED: 15173897

  6. Depression predicts elevated endothelin-1 in patients with coronary artery disease.
    
    Burg MMMartens EJCollins DSoufer R
    Psychosom Med, (1):2-6 2010
    MED: 20947777

  7. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.
    
    Chuengsamarn SRattanamongkolgul SPhonrat BTungtrongchitr RJirawatnotai S
    J Nutr Biochem, (2):144-150 2013
    MED: 24445038

  8. The role of substance P in stress and anxiety responses.
    
    Ebner KSingewald N
    Amino Acids, (3):251-272 2006
    MED: 16820980

  9. Differential effects of curcumin on vasoactive factors in the diabetic rat heart.
    
    Farhangkhoee HKhan ZAChen SChakrabarti S
    Nutr Metab (Lond), 27 2006
    MED: 16848894

  10. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment.
    
    Galecki PSzemraj JBienkiewicz MFlorkowski AGalecka E
    Pharmacol Rep, (3):436-447 2009
    MED: 19605942

  11. Cytokine modulation by endothelin-1 and possible therapeutic implications in systemic sclerosis.
    
    Giordano NPapakostas PPecetti GNuti R
    
    J Biol Regul Homeost Agents, (4):487-492 2011
    MED: 22217982

  12. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder.
    
    Hlavacova NWes PDOndrejcakova MFlynn MEPoundstone PKBabic SMurck HJezova D
    Int J Neuropsychopharmacol, (2):247-265 2011
    MED: 21375792

  13. Endothelin concentrations in cerebrospinal fluid in depressive patients
    
    Hoffman
    Lancet, (8678–8679) 1989

  14. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
    
    Holmes AHeilig MRupniak NMSteckler TGriebel G
    Trends Pharmacol Sci, (11):580-588 2003
    MED: 14607081

  15. Blunted aldosterone and ACTH release after human CRH administration in depressed patients.
    
    Holsboer FGerken AStalla GKMuller OA
    Am J Psychiatry, (2):229-231 1987
    MED: 3028185

  16. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
    
    Howren MBLamkin DMSuls J
    Psychosom Med, (2):171-186 2009
    MED: 19188531

  17. Attenuation of endothelin-1-induced PKB and ERK1/2 signaling, as well as Egr-1 expression, by curcumin in A-10 vascular smooth muscle cells.
    
    Kapakos GYoureva VSrivastava AK
    Can J Physiol Pharmacol, (9):1277-1285 2012
    MED: 22913328

  18. Endothelin--biology and disease.
    
    Khimji AKRockey DC
    Cell Signal, (11):1615-1625 2010
    MED: 20466059

  19. Comparison of the effects of endothelin-1 and -3 on secretion of pituitary hormones in healthy male volunteers.
    
    Kiefer F, Kellner MJahn HWiedemann K
    Exp Clin Endocrinol Diabetes, (5):378-381 2000
    MED: 10989958

  20. Low doses of curcumin protect alcohol-induced liver damage by modulation of the alcohol metabolic pathway, CYP2E1 and AMPK
    
    Lee
    Life Sci., (18–19) 2013

  21. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression.
    
    Leonard BMaes M
    Neurosci Biobehav Rev, (2):764-785 2011
    MED: 22197082

  22. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects.
    
    Lopresti ALHood SDDrummond PD
    J Psychopharmacol, (12):1512-1524 2012
    MED: 23035031

  23. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study.
    
    Lopresti ALMaes MMaker GLHood SDDrummond PD
    J Affect Disord, 368-375 2014
    MED: 25046624

  24. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers.
    
    Lopresti ALMaker GLHood SDDrummond PD
    Prog Neuropsychopharmacol Biol Psychiatry, 102-111 2013
    MED: 24104186

  25. The leptin hypothesis of depression: a potential link between mood disorders and obesity?
    
    Lu XY
    Curr Opin Pharmacol, (6):648-652 2007
    MED: 18032111

  26. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression
    
    Maes
    Neuroendocrinology Lett., (1) 2008

  27. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes.
    
    Maes MKubera MLeunis JCBerk MGeffard MBosmans E
    Acta Psychiatr Scand, (5):344-354 2012
    MED: 22900942

  28. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome
    
    Maes
    Neuroendocrinol. Lett., (6) 2009

  29. The DEX/CRH test for major depression: a potentially useful diagnostic test.
    
    Mokhtari MArfken CBoutros N
    Psychiatry Res, (2):131-139 2013
    MED: 23291044

  30. Molecular and anatomical determinants of central leptin resistance.
    
    Munzberg HMyers MG Jr
    Nat Neurosci, (5):566-570 2005
    MED: 15856064

  31. Role of brain thromboxane A2 in the release of noradrenaline and adrenaline from adrenal medulla in rats.
    
    Okada SMurakami YYokotani K
    Eur J Pharmacol, (1-3):125-131 2003
    MED: 12706465

  32. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial.
    
    Panahi YSaadat ABeiraghdar FSahebkar A
    Phytother Res, (10):1461-1467 2014
    MED: 24648302

  33. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial.
    
    Panahi YSahebkar AAmiri MDavoudi SMBeiraghdar FHoseininejad SLKolivand M
    Br J Nutr, (7):1272-1279 2011
    MED: 22099425

  34. High plasma concentrations of cortisol and thromboxane B2 in patients with depression.
    
    Piccirillo GFimognari FLInfantino VMonteleone GFimognari GBFalletti DMarigliano V
    
    Am J Med Sci, (3):228-232 1994
    MED: 8160715

  35. Role of endothelin-1 receptor blockers on hemodynamic parameters and oxidative stress.
    
    Piechota APolanczyk AGoraca A
    Pharmacol Rep, (1):28-34 2010
    MED: 20360613

  36. Bosentan, a mixed endothelin receptor antagonist, induces antidepressant-like activity in mice.
    
    Pinho-Ribeiro FABorghi SMStaurengo-Ferrari LFilgueiras GBEstanislau CVerri WA Jr
    Neurosci Lett, 57-61 2013
    MED: 24361136

  37. The Inventory of Depressive Symptomatology (IDS): psychometric properties.
    
    Rush AJGullion CMBasco MRJarrett RBTrivedi MH
    Psychol Med, (3):477-486 1996
    MED: 8733206

  38. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial.
    
    Sanmukhani JSatodia VTrivedi JPatel TTiwari DPanchal BGoel ATripathi CB
    Phytother Res, (4):579-585 2013
    MED: 23832433

  39. Pharmacology and physiopathology of the brain endothelin system: an overview.
    
    Schinelli S
    Curr Med Chem, (6):627-638 2006
    MED: 16529555

  40. Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure.
    
    Sellers MMStallone JN
    Am J Physiol Heart Circ Physiol, (5):H1978-86 2008
    MED: 18310512

  41. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy.
    
    Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, Finkel MS, Krishnan KR, Gaffney M, Harrison W, Califf RM, O'Connor CMSertraline AntiDepressant Heart Attack Randomized Trial Study Group
    Circulation, (8):939-944 2003
    MED: 12912814

  42. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling.
    
    Shah BHNawaz ZPertani SARoomi AMahmood HSaeed SAGilani AH
    Biochem Pharmacol, (7):1167-1172 1999
    MED: 10484074

  43. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
    
    Sheehan
    J. Clin. Psychiatry, (Suppl. 20):S22- 1998

  44. Endothelin and dopamine release.
    
    van den Buuse MWebber KM
    Prog Neurobiol, (4):385-405 2000
    MED: 10670706

  45. Lifetime history of depression, type 2 diabetes, and endothelial reactivity to acute stress in postmenopausal women.
    
    Wagner JATennen HFinan PHWhite WBBurg MMGhuman N
    Int J Behav Med, (4):503-511 2012
    MED: 21964983

  46. The role of nuclear factor-kappa B in bacterial translocation in cholestatic rats.
    
    Weber-Mzell DZaupa PPetnehazy TKobayashi HSchimpl GFeierl GKotanko PHollwarth M
    Pediatr Surg Int, (1):43-49 2006
    MED: 16333628

  47. [Effects of qingyi II granules on intestinal bacterial translocation in rats with acute necrotizing pancreatitis].
    
    Xiao QCDui DHLan TG
    Zhongguo Zhong Xi Yi Jie He Za Zhi, (10):905-909 2009
    MED: 20073222

  48. Leptin signaling and leptin resistance.
    
    Zhou YRui L
    Front Med, (2):207-222 2013
    MED: 23580174

  49. Leptin as a neuroactive agent.
    
    Zupancic MLMahajan A
    Psychosom Med, (5):407-414 2011
    MED: 21597032
    
    
    

Request More Information

We'll never share your email with anyone else.
We'll never share your email with anyone else.
We'll never share your company with anyone else.
We'll never share your country with anyone else.
We'll never share your contactNumber with anyone else.

We are always supporting our network of practitioners

Subscribe to our premium service for people like you who are passionate for science and want to know more about nature and its phenomena. Get detailed reports, methods and many more.

Increase your business growth potential with our patented extracts

Let’s collaborate to refine your ideas or built from scratch

Arjuna Natural

Arjuna Natural Ltd is India’s leading manufacturer and exporter of standardized botanical extracts for pharmaceutical and nutraceutical industries for more than two decades. Established in 1989, the company has grown...Read More

Get all the Updates about us!

For sales enquiries please email us at
sales@arjunanatural.com